Nexsen Limited (ASX:NXN)

Market Cap	23.02M
Revenue (ttm)	n/a
Net Income	-6.55M
EPS	-0.04
Shares Out	200.20M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	346,887
Open	0.1250
Previous Close	0.1250
Day's Range	0.1050 - 0.1300
52-Week Range	0.1050 - 0.3450
Beta	n/a
Analysts	n/a
Price Target	n/a
Earnings Date	Sep 4, 2026

About Nexsen

Nexsen Limited operates as a nanobiotechnology company that develops proprietary biosensing platforms for rapid, high-precision point-of-care (POC) medical diagnostics and point-of-use sensing for human health, food and animal health, and biosecurity applications. The company offers Group B Streptococcus (GBS) rapid sensor; StrepSure, a diagnostic for the detection of human GBS in expectant mothers; kidney diseases, a POC tests for the screening, detection, and ongoing monitoring of various subsets of acute kidney injury and chronic kidney dise...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2021
• Country: Australia
• Stock Exchange: Australian Securities Exchange
• Ticker Symbol: NXN

Financial Performance

Data Sources: S&P Global Market Intelligence and Financial Modeling Prep

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Financial Modeling Prep.

Last checked:

Oct 1, 2026

Data Sources Report a data error